BioSig Submits Application to Systems for Award Management (SAM) with U.S. Government
July 10 2020 - 1:15PM
BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a
medical technology company commercializing a proprietary biomedical
signal processing platform designed to improve signal fidelity and
uncover the full range of ECG and intra-cardiac signals, today
announced that the Company has submitted its application to Systems
for Award Management (SAM).
Upon completion of its registration with SAM, BioSig, along with
its wholly owned subsidiary ViralClear, will become eligible to
conduct business with the federal government. This includes the
ability to apply and be awarded government contracts, assistance
and grant programs. Additionally, government agencies will be able
to search for BioSig when contracts that fit the Company become
available.
BioSig expects to receive its Commercial and Government Entity
(CAGE) code, required to begin business operations with the federal
government, within the next two weeks.
About SAMThe System for Award Management (SAM)
is a federal government owned and operated free website that
consolidates the capabilities in Central Contractor Registration
(CCR)/FedReg, Online Representations and Certifications
Applications (ORCA) and the Excluded Parties List System (EPLS).
Both current and potential government vendors are required to
register in SAM in order to be awarded contracts by the government.
SAM allows government agencies and contractors to search for
companies based on ability, size, location, experience, ownership,
and more. SAM allows users to search for firms certified by the SBA
under the 8(a) Development and Hubzone Programs. SAM validates the
vendor's information and electronically shares the secure and
encrypted data with the federal agencies' finance offices to
facilitate paperless payments through electronic funds transfer
(EFT). Additionally, SAM shares the data with government
procurement and electronic business systems.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com). The Company’s first product, PURE EP(tm)
System, is a computerized system intended for acquiring,
digitizing, amplifying, filtering, measuring and calculating,
displaying, recording and storing of electrocardiographic and
intracardiac signals for patients undergoing electrophysiology (EP)
procedures in an EP laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024